Business Context and Reporting Period
This Form 8-K is filed by Autonomix Medical, Inc. (AMIX) on February 28, 2025. The report addresses two primary matters: the entry into a new securities sales agreement and the retrospective restatement of financial data to reflect a 1-for-20 reverse stock split effected on October 24, 2024.
Key Financial Metrics and Capital Structure
- Capital Raising Facility: Entered into an At Market Issuance Sales Agreement with Ladenburg Thalmann & Co. Inc. to sell up to $2.1 million of common stock.
- Commission: The agent will receive a 3.0% commission on gross proceeds.
- Reverse Stock Split Impact:
- Outstanding shares reduced from approximately 23.0 million to 1.15 million.
- Net loss per share (basic and diluted) for the three months ended June 30, 2024, adjusted from $(0.14) pre-split to $(2.85) post-split.
- Weighted average shares outstanding for the three months ended June 30, 2024, adjusted from 18,902,248 to 945,382.
- Net Loss: The filing confirms a net loss of $2,699,000 for the three months ended June 30, 2024, and $865,000 for the same period in 2023. Total net loss amounts remain unchanged by the split.
Material Changes and Events
The most significant material change is the 1-for-20 reverse stock split, which proportionately adjusted share counts and exercise prices for options, warrants, and convertible notes. Additionally, the company is retrospectively updating its 2024 Form 10-K to reflect these split adjustments in the Management's Discussion and Analysis and Financial Statements sections.
Outlook, Risks, and Contingencies
- Use of Proceeds: Net proceeds from the new sales agreement are intended for working capital and general corporate purposes.
- Fractional Share Dispute: Following the reverse split, the company received a request from DTCC to issue 271,846 shares to account for fractional share rounding. Management disputes the accuracy of this calculation based on historical shareholder counts and has initiated an inquiry. The company is not currently issuing these shares but acknowledges potential liability if the issuance is ultimately required.
- Market Conditions: Sales under the new agreement are discretionary and dependent on market conditions and capital needs.
Investor Verification Checklist
- Verify the status of the inquiry regarding the 271,846 disputed fractional shares and any potential liability exposure.
- Review the full text of the At Market Issuance Sales Agreement (Exhibit 1.1) for specific termination rights and price limitations.
- Confirm the updated share count and per-share metrics in the revised 2024 Form 10-K sections (Exhibit 99.1).
- Monitor the company's cash burn rate relative to the $2.1 million potential capital raise to assess liquidity runway.